ES3023044T3 - Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein - Google Patents
Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein Download PDFInfo
- Publication number
- ES3023044T3 ES3023044T3 ES18786587T ES18786587T ES3023044T3 ES 3023044 T3 ES3023044 T3 ES 3023044T3 ES 18786587 T ES18786587 T ES 18786587T ES 18786587 T ES18786587 T ES 18786587T ES 3023044 T3 ES3023044 T3 ES 3023044T3
- Authority
- ES
- Spain
- Prior art keywords
- pericarditis
- rilonacept
- subject
- days
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563387P | 2017-09-26 | 2017-09-26 | |
| US201862616819P | 2018-01-12 | 2018-01-12 | |
| US201862625075P | 2018-02-01 | 2018-02-01 | |
| US201862639425P | 2018-03-06 | 2018-03-06 | |
| US201862654291P | 2018-04-06 | 2018-04-06 | |
| US201862691552P | 2018-06-28 | 2018-06-28 | |
| US201862716331P | 2018-08-08 | 2018-08-08 | |
| PCT/US2018/052985 WO2019067639A1 (en) | 2017-09-26 | 2018-09-26 | TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3023044T3 true ES3023044T3 (en) | 2025-05-29 |
Family
ID=63858163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18786587T Active ES3023044T3 (en) | 2017-09-26 | 2018-09-26 | Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11026997B2 (https=) |
| EP (2) | EP3687562B1 (https=) |
| JP (3) | JP7301815B2 (https=) |
| CA (1) | CA3075538A1 (https=) |
| DK (1) | DK3687562T3 (https=) |
| ES (1) | ES3023044T3 (https=) |
| FI (1) | FI3687562T3 (https=) |
| HU (1) | HUE071206T2 (https=) |
| PL (1) | PL3687562T3 (https=) |
| PT (1) | PT3687562T (https=) |
| SI (1) | SI3687562T1 (https=) |
| WO (1) | WO2019067639A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171948A1 (en) * | 2005-02-02 | 2006-08-03 | Weinstein Steven P | Methods of using IL-1 antagonists to reduce C-reactive protein |
| WO2012078101A1 (en) | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
| WO2014035361A1 (en) | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
| JP6225197B2 (ja) | 2013-02-15 | 2017-11-01 | アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ | ＩＬ−１β阻害剤組成物およびその使用 |
| WO2015147789A1 (en) | 2014-03-24 | 2015-10-01 | R-Pharm Overseas, Inc. | Human il 1-r1 derived inhibitor of il-1b |
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
-
2018
- 2018-09-26 CA CA3075538A patent/CA3075538A1/en active Pending
- 2018-09-26 FI FIEP18786587.8T patent/FI3687562T3/fi active
- 2018-09-26 PL PL18786587.8T patent/PL3687562T3/pl unknown
- 2018-09-26 WO PCT/US2018/052985 patent/WO2019067639A1/en not_active Ceased
- 2018-09-26 PT PT187865878T patent/PT3687562T/pt unknown
- 2018-09-26 HU HUE18786587A patent/HUE071206T2/hu unknown
- 2018-09-26 DK DK18786587.8T patent/DK3687562T3/da active
- 2018-09-26 US US16/143,391 patent/US11026997B2/en active Active
- 2018-09-26 ES ES18786587T patent/ES3023044T3/es active Active
- 2018-09-26 SI SI201831227T patent/SI3687562T1/sl unknown
- 2018-09-26 EP EP18786587.8A patent/EP3687562B1/en active Active
- 2018-09-26 JP JP2020516827A patent/JP7301815B2/ja active Active
- 2018-09-26 EP EP25150543.4A patent/EP4541367A3/en active Pending
-
2021
- 2021-03-22 US US17/208,409 patent/US20210283224A1/en not_active Abandoned
- 2021-11-16 US US17/527,956 patent/US11464830B2/en active Active
-
2022
- 2022-09-02 US US17/929,458 patent/US11944666B2/en active Active
- 2022-09-02 US US17/929,572 patent/US20220409699A1/en not_active Abandoned
-
2023
- 2023-03-14 JP JP2023039474A patent/JP7564270B2/ja active Active
- 2023-05-05 US US18/313,134 patent/US11844765B2/en active Active
-
2024
- 2024-05-22 US US18/671,801 patent/US12201673B2/en active Active
- 2024-07-09 JP JP2024110108A patent/JP2024133112A/ja active Pending
-
2025
- 2025-07-23 US US19/278,317 patent/US20250345396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072102A1 (en) | 2022-03-10 |
| EP3687562A1 (en) | 2020-08-05 |
| EP3687562B1 (en) | 2025-03-19 |
| US20240293510A1 (en) | 2024-09-05 |
| DK3687562T3 (da) | 2025-04-14 |
| JP7564270B2 (ja) | 2024-10-08 |
| JP7301815B2 (ja) | 2023-07-03 |
| US20210283224A1 (en) | 2021-09-16 |
| EP4541367A3 (en) | 2025-07-30 |
| US11464830B2 (en) | 2022-10-11 |
| SI3687562T1 (sl) | 2025-06-30 |
| US20220409699A1 (en) | 2022-12-29 |
| US12201673B2 (en) | 2025-01-21 |
| WO2019067639A1 (en) | 2019-04-04 |
| JP2024133112A (ja) | 2024-10-01 |
| PT3687562T (pt) | 2025-04-03 |
| EP4541367A2 (en) | 2025-04-23 |
| HUE071206T2 (hu) | 2025-08-28 |
| US20250345396A1 (en) | 2025-11-13 |
| US20230012740A1 (en) | 2023-01-19 |
| US20230346887A1 (en) | 2023-11-02 |
| US20190151417A1 (en) | 2019-05-23 |
| JP2020535140A (ja) | 2020-12-03 |
| CA3075538A1 (en) | 2019-04-04 |
| US11026997B2 (en) | 2021-06-08 |
| US11844765B2 (en) | 2023-12-19 |
| JP2023063426A (ja) | 2023-05-09 |
| US11944666B2 (en) | 2024-04-02 |
| FI3687562T3 (fi) | 2025-04-25 |
| PL3687562T3 (pl) | 2025-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2979034T3 (es) | Procedimientos de tratamiento del síndrome de Lennox-Gastaut mediante el uso de fenfluramina | |
| US20250345396A1 (en) | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein | |
| PT2275086E (pt) | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração | |
| ES3004516T3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| BRPI0711823A2 (pt) | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig | |
| US20260070997A1 (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome | |
| AU2023233094A1 (en) | Anti-inflammatory agents | |
| RU2464023C2 (ru) | Лекарственное средство для лечения фибромиалгии | |
| BR112020021739A2 (pt) | tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta | |
| HK40035543A (en) | Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein | |
| HK40035543B (en) | Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein | |
| US20200000874A1 (en) | Peptides and methods of treating dystrophy-related disorders using the same | |
| TW202337443A (zh) | 使用ｔｌｒ７／８拮抗劑治療ｓｊｏｇｒｅｎ氏症候群或混合性結締組織病之方法 | |
| JP2020535140A5 (https=) | ||
| US20250032449A1 (en) | Treatment of rheumatoid arthritis | |
| AU2018225163A1 (en) | Peptides and methods of treating dystrophy-related disorders using the same | |
| WO2025124760A1 (en) | Treatment of subpopulation of patients with rheumatoid arthritis | |
| BR122025027043A2 (pt) | USO DE ANTICORPO ANTI-OSMRbeta | |
| Nord et al. | Do Corticotropin Releasing Factor-1 Receptors Influence Colonic Transit and Bowel Function in Females with Irritable Bowel Syndrome? Seth Sweetser, MD Michael Camilleri, MD | |
| KR20120067783A (ko) | 섬유근육통 치료용 의약 조성물 |